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Systemic sclerosis (scleroderma 
or SSc) is the name for a group of 
progressive diseases, all of which involve 
the abnormal growth of connective 
tissue. They are chronic degenerative 
disorders in which there is widespread 
vascular deterioration and tissue loss. 
The recognition of SSc dates back 
many years. Indeed, the characteristic 
stretched thickening of the skin was 
probably ﬁ  rst described by Hippocrates. 
A more deﬁ  nitive description of the 
condition was made by Carlo Curzio 
in 1753, who described a patient as 
having wood-like skin with “tight 
eyelids, difﬁ  culty in opening her mouth, 
coldness of her skin.” 
The etiology of SSc is still not 
completely understood, but appears 
to be autoimmune. Downstream of the 
immune activation, the molecules that 
have been implicated are the proﬁ  brotic 
cytokines, such as transforming growth 
factor-beta (TGFβ), interleukin-4 (IL-4), 
platelet-derived growth factor (PDGF), 
and connective tissue growth factor, all 
of which can cause ﬁ  brosis. In addition 
to the proﬁ  brotic effects, TGFβ and PDGF 
may also contribute to vasculopathy. 
Furthermore, the vascular changes in SSc 
skin lesions are associated with anti-
endothelial cell autoantibodies. 
One problem in the research on SSc 
has been ﬁ  nding an appropriate animal 
model. One such model has now been 
developed: the transplantation of skin 
samples from patients with SSc into 
immunodeﬁ  cient mice. Without the 
interference of an effective murine 
immune system, it is possible to test the 
effect of various interventions on the 
patients’ skin samples.
In a paper in PLoS Medicine, Chunming 
Dong and colleagues used this model to 
investigate the effect of paclitaxel on SSc 
skin samples. Paclitaxel is an attractive 
drug because it stabilizes microtubules, 
which affect the propagation of TGFβ
signaling. TGFβ is a multifunctional 
regulatory cytokine involved in a large 
number of cellular activities. It initiates 
its effects by binding to and activating 
speciﬁ  c cell-surface receptors. These 
activated TGFβ receptors stimulate a 
family of proteins (R-Smads), some of 
which act to stimulate further TGFβ
signaling, and others of which act to 
inhibit it. The microtubules regulate the 
R-Smad access to and activation by TGFβ
receptors.
Dong and colleagues were able to 
show that in this model of SSc, paclitaxel 
markedly suppressed the activation of 
two of the Smads, Smad2 and Smad3, 
and, hence, collagen deposition in SSc 
grafts. They also showed that the SSc 
grafts had increased neovessel formation 
relative to normal grafts, regardless of 
paclitaxel treatment, thus indicating that 
paclitaxel did not have a negative effect 
on angiogenesis. In fact, they found that 
the neovascular cells were likely derived 
from the mouse hosts.
Do these ﬁ  ndings indicate that 
paclitaxel is a good drug for SSc? 
Certainly more work needs to be done 
before this can be said. A particular 
concern that paclitaxel can itself lead 
to ﬁ  brosis at high doses when used, for 
example, in the treatment of certain 
tumors (in contrast to low doses used 
here) needs to be assessed further. 
However, SSc is a difﬁ  cult progressive 
disease, and results such as these should 
be considered seriously as avenues for 
future therapies.
Liu X, Zhu S, Wang T, Hummers L, Wigley 
FM, et al. (2005) Paclitaxel modulates 
TGFβ signaling in scleroderma skin grafts 
in immunodeﬁ  cient mice. PLoS Med 2(12): 
e354. DOI: 10.1371/journal.pmed.0020354
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Suppression of Smad2 phosphorylation by 
paclitaxel in in SSc skin graft
Human parvovirus B19 (B19) can cause a wide range of 
conditions, which can depend to a large extent on an individual’s 
immunological and hematological status. In a normal host, 
parvovirus infection can be asymptomatic or cause a range of 
clinical syndromes, from erythema infectiosum (“slapped cheek” 
disease) to chronic arthritis. Hydrops fetalis and fetal death are 
complications of intrauterine B19 infection, and patients who are 
immunocompromised or who have hematologic disorders are at 
risk of aplastic anemia.
To date, it has been believed that clearance of acute infection 
is associated with the lifelong emergence of antiviral IgG, but 
there is increasing evidence for an important role for cellular 
immune responses, which suggests there might be more to the 
way the body deals with this virus. One previous study detected 
CD8+ T cell responses—which kill virus-infected cells by cytokine 
secretion—in three asymptomatic seropositive individuals. 
A better understanding of this aspect of the body’s immune 
response could have important implications not only for vaccine 
development and treatment for B19, but also for other viral 
infections. The long-lasting CD8+ T lymphocyte response means 
that parvovirus-based vectors could be considered in vaccine 
strategies for other infections. The identiﬁ  cation of B19 epitopes 
for CD8+ T lymphocytes also offers the chance to analyze the 
role of such effector cells in chronic arthritis, a disease in which 
B19 has been implicated. Better understanding of this response 
might also allow researchers to use B19 as a model for analyzing 
immunological memory, immunodominance, and the interplay 
between cellular and humoral immune responses to a common 
clinically relevant human pathogen.
In this month’s PLoS Medicine, Adiba Isa and colleagues 
describe evolution of long-lived CD8+ immune responses against 
B19 in 11 adults with primary B19 infection. The phenotype of 
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CD8+ T cells in acute B19 infection has not been studied before. 
Normally, the symptoms of this virus are short lived, but the 
immune responses showed here indicate sustained activity 
many months after initial infection. The team studied two groups 
of people: 11 who had been recently infected and ﬁ  ve who had 
the virus many years ago. CD8+ T cell responses were mapped 
using a screening system, which took advantage of the B19’s 
compact and stable viral genome. The researchers used human 
leukocyte antigen (HLA)–peptide multimeric complexes to 
detect CD8+ T cell responses during acute B19 infection.
The researchers believe their results show a new style of 
host–virus relationship in which an acute human viral infection 
induces persistent activated CD8+ T cell responses. They found 
that these responses continued to increase, in some cases 
for many months, long after acute symptoms had resolved—
something not seen with other viruses. For example, responses 
to HIV are strong in acute infection but typically decline as the 
virus is controlled.
Alongside the expansion of antiviral responses was the 
continued change in the B19 CD8+ T cells, as indicated by a 
range of markers. The evolution of markers could represent a 
maturation pathway, said the authors, driven by restimulation in 
vivo with antigen. 
This T cell response to B19 infection indicated the persistence 
of antigen long after the resolution of acute infection. However, 
the authors said the status of the virus postinfection is still not 
understood. For example, in this study, PCR analysis found B19 
DNA in the blood early on during infection, but assays were 
negative after 6–12 months when T cell populations remained 
active. The most likely reason for these immune responses is 
low-level replication at a tissue site for weeks or months after 
infection, suggest the authors. But this hypothesis can only be 
checked by more sensitive PCR assays. 
In addition, the relationship between joint or bone marrow 
pathology and T cell responses seen was not clear. In the patients 
with arthritis, the most active CD8+ T cell responses were seen at 
stages where joint symptoms had resolved.
Altogether, this study is the ﬁ  rst demonstration that a virus, 
not considered a true or classical persistent infection, can lead 
to a persistent activated CD8+ T cell response. It suggests that 
B19 persists after acute infection, provoking sustained activated 
CD8+ T cell responses, which might then play a role in viral 
clearance. A better understanding of cytotoxic T lymphocytes 
could improve understanding of the role of T cells in acute and 
persistent infections and be of great value in vaccine design and 
immunotherapy.
Isa A, Kasprowicz V, Norbeck O, Loughry A, Jeffery K, et al (2005) 
Prolonged activation of virus-speciﬁ  c CD8+ T cells after acute B19 
infection. DOI: 10.1371/journal.pmed.0020343
Malaria parasites invade human red 
blood cells, and it had already been 
recognized in the 1940s that diseases 
of red blood cells such as thalassemia 
and sickle-cell anemia, which are 
the most common group of genetic 
disorders in humans, are mainly found 
in populations exposed to malaria and 
their descendants. It seems that much 
of the genetic variation that affects the 
phenotype of red blood cells appears to 
have evolved due to natural selection by 
malaria. Susceptibility to malaria is also 
thought to be determined by genetic 
variation in the human immune system. 
We know less about the speciﬁ  c immune 
system genes involved, but this is an 
important area of research because 
researchers hope that understanding the 
molecular basis of natural immunity will 
speed up the development of an efﬁ  cient 
malaria vaccine. 
Rather than focusing on the 
identification of specific genes and 
gene variants, Margaret J. Mackinnon 
and colleagues are interested in the 
relative contributions of host genetics 
and other factors to the risk of malaria. 
To estimate the overall contribution 
of genetic factors to the difference in 
disease incidence between individuals 
within a population, one needs three 
types of data: (1) disease incidence 
for individuals over a certain period 
of time (to be able to determine an 
individual’s risk), (2) information on 
genetic relatedness of the individuals 
in the population, and (3) a setup 
in which individuals with different 
levels of relatedness share the 
same environment and/or where 
related individuals live in different 
environments. (The third condition 
is essential to distinguish between 
genetic and environmental effects.) 
Mackinnon and colleagues studied 
two populations of children from a 
malaria-endemic area in Kenya for which 
they could obtain the necessary data. 
In one case, they determined incidence 
of mild clinical malaria in 640 children 
over a period of ﬁ  ve years. Genetic 
relatedness between the children was 
determined by verbal interviews with 
their mothers. A typical household (i.e., 
shared environment) consisted of a 
group of three to six adjacent houses. 
Malaria Susceptibility—It’s Not All in the Genes
DOI: 10.1371/journal.pmed.0020411
DOI: 10.1371/journal.pmed.0020411.g001
Contributors to variation in mild malaria risk
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Within each household, the children 
formed several full-sibling, half-sibling, 
and ﬁ  rst-cousin groups. The second 
study monitored severe malaria that 
led to hospitalization and nonmalaria 
hospitalizations in 2,900 children, also 
over a ﬁ  ve-year period. This analysis 
concentrated on full-siblings. 
Using a standard statistical genetics 
method of relating similarity in 
phenotype to similarity in genotype, 
they found that host genetic factors 
accounted for approximately one-
quarter to one-third of the total variation 
in susceptibility in the populations to 
malaria. Of this percentage, only a small 
proportion could be attributed to the 
best known malaria resistance genes. 
This is consistent with other studies 
that suggest that malaria susceptibility 
is under the control of many different 
genes, with each individual gene having a 
relatively small epidemiological effect. 
When assessing the contribution 
of household factors, the researchers 
found that for mild clinical malaria, those 
factors accounted for slightly more 
than a quarter of the total variation. For 
hospitalized malaria, they contributed 
about 15%, and for hospitalizations with 
fever that turned out not to be malaria, 
they contributed approximately 35%. 
Overall, children living in the 10% of 
households with the highest malaria 
incidence had approximately twice as 
many infections per year than those 
living in the 10% of households with the 
lowest incidence. 
The researchers do not question the 
long-term beneﬁ  ts of understanding 
the genetic factors but conclude that 
“identifying and tackling the household 
effects must be the more efﬁ  cient route 
to reducing the burden of disease in 
malaria-endemic areas.” Factors such 
as suitable conditions for mosquitoes 
to breed and survive as well as human 
behavior are likely to play major roles. 
“We need to determine what makes 
the difference between low-risk and 
high-risk households,” Mackinnon 
says, “but whatever it is, it seems likely 
to be an easy target using tools such 
as education and the low-cost, low-
tech devices that we already have at 
hand such as bed nets, residual indoor 
spraying, and cleaning up backyards for 
mosquito breeding sites.” 
Mackinnon MJ, Mwangi TW, Snow RW, 
Marsh K, Williams TN (2005) Heritability 
of malaria in Africa. DOI: 10.1371/journal.
pmed.0020340
One of the tools in the scientist’s 
armory for resolving a medical issue or 
consolidating a body of clinical trials is 
the systematic review of the published 
medical literature. This technique 
involves doing a literature search and 
critical appraisal of individual studies, 
and in addition, may also use statistical 
techniques to combine the results of 
these studies. One of the aims of such 
reviews is to assess and then, ideally, 
include all appropriate studies that 
address the question of the review. But 
ﬁ  nding all studies is not always possible, 
and researchers have no way of knowing 
what they have missed. But does it matter 
if some studies are left out?
It would deﬁ  nitely matter if the 
missing studies differed signiﬁ  cantly 
from the included ones. And the worst-
case scenario is that the accumulation 
of evidence might point to the wrong 
answer if the studies included are 
unrepresentative of all those that have 
been done.
Studies of publication bias have noted 
that papers with signiﬁ  cant positive 
results are easier to ﬁ  nd than those with 
nonsigniﬁ  cant or negative results. As a 
result, overrepresentation of positive 
studies in systematic reviews might mean 
that such reviews are biased toward a 
positive result. Publication bias is just one 
in a group of related biases, all of which 
potentially lead to overrepresentation 
of signiﬁ  cant or positive studies in 
systematic reviews. Other types of bias 
include time lag bias (positive studies 
are more likely to be published rapidly); 
multiple publication bias (positive studies 
are more likely to be published more 
than once); citation bias (positive studies 
are more likely to be cited by others); and 
language bias (positive studies are more 
likely to be published in English).
In PLoS Medicine, John Ioannidis and 
colleagues have taken a closer look at bias 
in Chinese genetics studies. Research done 
in non-English-speaking countries has 
two outlets. A study might be published 
in English-language journals, which are 
usually indexed in major international 
bibliographic databases such as 
PubMed, or in domestic journals, many 
of which are not indexed in international 
databases. The Chinese literature is a 
prominent example of where domestic 
scientiﬁ  c journals are not catalogued in 
international databases. There is some 
evidence that the decision to publish in 
international versus domestic journals 
might be inﬂ  uenced by the results. For 
example, signiﬁ  cant results are often 
published in international journals, 
whereas nonsigniﬁ  cant results appear in 
the local literature, resulting in a language 
bias—although, the reverse situation has 
also been described. 
Genetics studies pose particular 
problems for impartial reporting. There 
are millions of polymorphisms in the 
human genome, and an exponentially 
increasing number of studies are trying 
to associate genetic polymorphisms with 
risk of disease or treatment outcomes. 
Selective publication might invalidate the 
overall picture of genetic risk factors.
The authors examined 13 gene–
disease associations. Studies were more 
likely to be published when the disease 
was considered common in China. They 
found 161 Chinese studies on 12 of these 
gene–disease associations, only 20 of 
which were indexed in PubMed. Chinese 
studies had signiﬁ  cantly more prominent 
genetic effects than non-Chinese 
studies, and 48% were statistically 
signiﬁ  cant per se, despite their smaller 
sample size. Moreover, the largest, most 
exaggerated genetic effects were often 
seen in PubMed-indexed Chinese studies. 
Chinese studies usually appeared several 
years after their equivalent was ﬁ  rst 
postulated in the world literature. 
The larger genetic effects in Chinese 
studies are unlikely to reﬂ  ect genuine 
heterogeneity and are more likely to do 
with publication bias operating within 
the Chinese literature, say the authors. 
It is possible that there was reluctance 
to submit and publish negative or 
inconclusive results when a large body 
Bias in Reporting of Genetic Association Studies
DOI: 10.1371/journal.pmed.0020419
DOI: 10.1371/journal.pmed.0020419.g001
Different results in local literature studies
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of English-language literature has shown 
the presence of genetic effects. However, 
such “forced” conﬁ  rmation negates the 
importance of independent conﬁ  rmation 
of research results. This problem is 
probably not limited to the Chinese 
literature. These phenomena haven’t been 
noted in molecular medicine before, but 
could become a serious problem in such a 
fast-moving ﬁ  eld. Moreover, the inclusion 
of poor-quality research and additional 
selectively reported data may contaminate 
the better literature rather than provide a 
more accurate, comprehensive picture.
The ﬁ  ndings have two broad 
implications. First, language bias might 
be important to consider in meta-
analyses of observational studies, where 
its effect might be larger than its effect 
on randomized evidence. Second, 
because human genome epidemiology 
is a global enterprise, a comprehensive 
global view is important to help decipher 
artifacts from true genetic effects. The 
Chinese literature in particular will be 
essential for the evaluation of evidence 
on genetic risk factors. China is making 
rapid scientiﬁ  c progress in this ﬁ  eld and 
joining in international collaborative 
projects, such as the Human Genome 
Project. To develop a global perspective, 
one way forward might be for all 
investigators working on the genetics 
of a speciﬁ  c disease to register with 
a common network, making it easier 
to trace additional unpublished or 
nonindexed data. 
Pan Z, Trikalinos TA, Kavvoura FK, Lau 
J, Ioannidis JPA (2005) Local literature 
bias in genetic epidemiology: An empirical 
evaluation of the Chinese literature. DOI: 
10.1371/journal.pmed.0020334
Every year at least 30 million women in malarious areas of 
Africa become pregnant. The symptoms and complications of 
malaria during pregnancy differ with the intensity of malaria 
transmission and with the level of immunity acquired by the 
pregnant woman. In areas where malaria is endemic, most 
adult women have developed sufficient immunity such that, 
even during pregnancy, P. falciparum infection does not 
usually result in fever or other clinical symptoms. In these 
areas, the principal impact of malaria infection is due to 
the presence of parasites in the placenta. Placental malaria 
frequently results in low birth weight, and estimates suggest 
that in endemic areas 19% of cases of infant low birth weight 
are due to malaria, and that 6% of infant deaths are due to 
low birth weight caused by malaria.
In addition to affecting birth weight, placental malaria 
might increase the susceptibility of infants to malaria, but 
so far studies on this subject have been inconclusive. Patrick 
Duffy and colleagues examined the effect of placental malaria 
on infant malaria susceptibility in a prospective cohort study 
of newborns in a malaria-endemic area. They monitored 
parasitemia in 453 infants in a region of northeastern Tanzania 
where malaria transmission is very high (with an estimated 400 
infective mosquito bites per individual per year). Sixty-nine 
of the infants were born to mothers with placental malaria. 
Placental malaria is caused by a different form of the malaria 
parasite, which does not commonly infect nonpregnant 
individuals. Even in endemic areas, women, therefore, lack 
immunity to the placenta-speciﬁ  c form of the parasite prior to 
their ﬁ  rst pregnancy, but acquire it over successive pregnancies. 
As a consequence, placental malaria is most frequent 
and severe in ﬁ  rst-time mothers. Of the 69 mothers with 
placental malaria in this study, 45% were ﬁ  rst-time mothers 
(or primigravid), 38% were giving birth to their second child 
(secundigravid), and 17% had had multiple prior pregnancies 
(multigravid). 
Overall, infants of mothers with placental malaria were 41% 
more likely to experience malaria parasitemia themselves 
in the first year of life. However, the odds of parasitemia 
throughout infancy were also strongly influenced by the 
mother’s gravidity. The researchers found a surprising 
protective effect of placental malaria of primigravid mothers 
on their firstborns’ risk of parasitemia. Placental malaria of 
multigravid women, on the other hand, significantly increased 
risk of parasitemia during infancy. And even in the absence of 
placental malaria, firstborn children were less likely to have 
parasitemia than infants born to multigravid mothers. These 
results suggest that risk of parasitemia during infancy was 
modified by an interaction between placental malaria and 
gravidity. 
Duffy and colleagues speculate that the stronger 
inﬂ  ammatory response to placental malaria in ﬁ  rst-time 
mothers could reduce congenital transmission or somehow 
strengthen the fetal immune system against malaria. They 
also suggest that the opposing effects of placental malaria 
in different gravid groups might explain why earlier studies 
found no signiﬁ  cant risk between placental malaria and malaria 
susceptibility during the ﬁ  rst two years of life. The results here 
are provocative but preliminary. Additional larger studies are 
necessary to conclusively demonstrate an interaction between 
placental malaria and gravidity in infant malaria susceptibility, 
and to examine potential modulation of congenital malaria 
transmission and infant immunity to the parasite by placental 
inﬂ  ammation. 
Mutabingwa TK, Bolla MC, Li JL, Domingo GJ, Li X, et al. (2005) 
Maternal malaria and gravidity interact to modify infant susceptibility 
to malaria. DOI: 10.1371/journal.pmed.0020407
Surprising Effects of Maternal Malaria and Gravidity on Infant Malaria Burden
DOI: 10.1371/journal.pmed.0020413
DOI: 10.1371/journal.pmed.0020413.g001
Section from a malaria-infected placenta (Photo: Michal Fried)
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There are many instances in medical 
practice of an intervention becoming 
adopted despite evidence of it not being 
of the highest quality. The converse is 
also true; despite good evidence for the 
effectiveness of a treatment, it may not 
be implemented for a variety of different 
reasons. Reasons may be social or 
ﬁ  nancial or due to a lack of knowledge of 
the beneﬁ  ts of the intervention.
In this issue of PLoS Medicine, Randall 
Stafford and colleagues investigate the 
use of one such underused intervention, 
aspirin, in the United States. Many studies 
have shown that aspirin is beneﬁ  cial as 
both primary and secondary prevention 
of cardiovascular disease in a wide range 
of patients who do not otherwise have 
contraindications such as increased 
bleeding risk. For example, the American 
College of Chest Physicians has issued 
a grade 1A recommendation (such 
recommendations are “strong and indicate 
that the beneﬁ  ts … outweigh risks, 
burden, and costs”) that aspirin be used for 
secondary prevention of acute coronary 
events. The American Diabetes Association 
recommends aspirin to all people with 
diabetes over 40, or younger if they have 
additional cardiovascular risk factors. 
Stafford and colleagues used the 
1993–2003 US National Ambulatory 
Medical Care Survey (NAMCS) and 
National Hospital Ambulatory Medical 
Care Survey (NHAMCS) to estimate 
aspirin use by cardiovascular risk. These 
validated surveys are comprehensive 
collections of data on prescribing; NAMCS 
captures health-care services provided by 
private ofﬁ  ce-based physicians, whereas 
NHAMCS captures services offered at 
hospital outpatient departments. Their 
data are representative of care provided 
in a huge number of outpatient visits—
around 750 million in 2003. 
What the authors found was that 
although aspirin use increased steadily 
over the time of the survey, even at its 
highest—in 2003—it was prescribed 
at only 32.8 % of high-risk visits; for 
low-risk visits, the rate was just 1%–3%. 
They also compared prescribing of 
aspirin and statins, and found that the 
rate of prescribing of statins overtook 
that of aspirin in1997–1998, and rose 
steadily thereafter. There were also 
substantial differences in the age of 
patients prescribed aspirin, with lower 
usage found in those below 45 than 
those 45 or above, and lower usage in 
women. Also, there was lower prescribing 
by noncardiologists than cardiologists, 
in private practices versus hospital 
outpatient departments, and at return 
visits versus ﬁ  rst-time visits. In people 
with diabetes who were at intermediate 
risk, aspirin use was only 11.7% by 2003. 
So despite all the recommendations 
and evidence for the use of aspirin, rates 
of prescribing are low, even for conditions 
where clear guidelines exist. As the authors 
say, “gaps observed with secondary 
prevention are particularly concerning, 
given the existence of conclusive clinical 
evidence and unequivocal practice 
guidelines.” One particular cause of this 
lack of adherence to guidelines may be 
speciﬁ  c to the US—the less restrictive 
regulations on newer drug advertising 
of drugs such as statins, particularly 
widespread consumer advertising. 
Hence, despite good evidence and the 
cost effectiveness of aspirin, statins are 
increasingly preferred over aspirin.
As the authors conclude, “marked 
changes in clinical practice are unlikely 
to occur unless more aggressive, 
innovative means are implemented to 
enhance health-care provider and patient 
adherence to consensus guidelines.”
Stafford RS, Monti V, Ma J (2005) 
Underutilization of aspirin persists in US 
ambulatory care for the secondary and 
primary prevention of cardiovascular 
disease. DOI: 10.1371/journal.
pmed.0020353
Flying in the Face of the Evidence; Low Aspirin Use in the US Outpatient Setting
DOI: 10.1371/journal.pmed.0020416
Dementia is a common condition in 
the elderly; around 6% of people over 
65 and up to 50% over 90 have some 
form of dementia, about half of which 
are due to Alzheimer disease (AD). The 
dementia caused by AD has an insidious 
onset and a progressive course with 
slow deterioration in cerebral function, 
initially affecting short-term memory and 
cognitive skills, and later speech, motor 
functions, and personality. Death usually 
occurs within four to eight years after 
diagnosis.
The aim of treatment is to reverse 
cognitive decline and improve behavioral 
and psychological functions. Key 
questions in Alzheimer research are how 
best to halt the progression of disease 
to maintain and if possible restore 
cognitive skills, and when to initiate such 
interventions in order to be effective. 
AD is identiﬁ  ed at autopsy by the 
presence of hallmark lesions in key 
regions of the brain. These lesions, 
known as amyloid plaques, are formed 
by the aggregation of small peptides, 
called amyloid β peptide (Aβ), that are 
produced when amyloid precursor 
protein (APP) is cleaved by the action of 
two enzymes, β-APP cleaving enzyme 
and γ-secretase. One approach to the 
treatment of Alzheimer is, therefore, 
limiting the production of Aβ from its 
precursor by inhibiting one or both of 
these enzymes. However, it is not yet clear 
whether this approach will prevent the 
brain lesions and cognitive symptoms 
from getting worse, and if it will then 
promote the removal of preexisting 
plaques and reverse cognitive decline.
To answer such questions, Joanna 
Jankowsky and colleagues have 
developed mice that produce Aβ at 
levels sufﬁ  cient to induce severe amyloid 
burden by six months of age. The 
animals carry an additional transgene 
that acts as a switch to control when 
Aβ is produced. Commonly known as 
the tet-off system, the switch is turned 
off when the mice are fed tetracycline 
Will Stopping Aβ Production Reverse the Damage in Alzheimer Disease?
DOI: 10.1371/journal.pmed.0020418
DOI: 10.1371/journal.pmed.0020418.g001
Amyloid plaques, shown here as false-color 
images, are highly stable structures in vivo
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Type 2 diabetes has been loosely 
deﬁ  ned as “adult onset” diabetes, but as 
diabetes becomes more common, cases 
are being diagnosed in younger people 
and children. In determining the risk 
of developing diabetes, environmental 
factors, such as food intake and exercise, 
are known to have an important role; 
most people with type 2 diabetes are 
either overweight or obese. Inherited 
factors are also important, but the 
genes involved remain poorly deﬁ  ned. 
In rare forms of diabetes, mutations of 
one gene can result in disease, whereas 
in type 2 diabetes, many genes are 
thought to be involved. One difﬁ  culty in 
understanding the genetic role is that 
genes associated with diabetes might 
show only a subtle variation in their 
sequence, and these variations may be 
extremely common. Hence, it can be 
very hard to link such common gene 
variations, known as single nucleotide 
polymorphisms (SNPs), with increased 
risk of developing diabetes. 
One method of ﬁ  nding these 
diabetes genes is by whole-genome 
linkage studies in which associations 
between parts of the genome and risk 
of developing diabetes are looked for. 
Studies so far have identiﬁ  ed several 
candidate genes associated with type 
2 diabetes, although many results have 
been difﬁ  cult to replicate. The list of 
genes for which there is good evidence 
from meta-analyses includes genes 
encoding for PPARG, calpain 10, Kir 6.2, 
and insulin receptor substrate-1 (IRS1).
These genes have a variety of effects; 
PPARG P12A polymorphism is associated 
with enhanced insulin sensitivity and 
protects against type 2 diabetes. Two 
SNPs in the gene encoding for cystein 
protease calpain 10 (CAPN10) confer 
increased susceptibility to insulin 
resistance and type 2 diabetes. Kir 6.2 is 
involved in glucose-stimulated insulin 
secretion in pancreatic cells. And carriers 
of a polymorphism in the IRS1 gene have 
been shown to have reduced islet insulin 
content in pancreatic islets.
In this issue of PLoS Medicine, Valeriya 
Lyssenko and colleagues from Lund 
University sought to consolidate previous 
work by studying the predictive value of 
these variants for type 2 diabetes side 
by side in the largest study of its kind 
to date. They investigated the effect of 
these gene variants in 2,293 nondiabetic 
people aged 18–70 years old in western 
Finland—the Botnia study—over a 
median of six, range 2–12, years. In 
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or its analog, doxycycline. Once given 
the drug, Aβ production in the brains 
of these mice diminishes by more than 
95% of pretreatment levels within two 
weeks. This system, thus, mimics the 
effect of shutting down Aβ production 
with enzyme inhibitors that are being 
developed for use in human patients.
In the study, the researchers used 
doxycycline to switch off production of 
Aβ, and examined what happened to the 
amyloid pathology. Not surprisingly, the 
increase in number and size of amyloid 
lesions that normally occurs as the mice 
get older was completely prevented 
by suppressing Aβ production. 
However, the researchers also found 
no substantial clearance of preexisitng 
plaques, even after six months of 
treatment (one-quarter of the normal 
mouse lifespan). 
What do these ﬁ  ndings mean for 
human Alzheimer research? First, the 
study provides evidence that the lesions 
found in AD may be more difﬁ  cult 
for the brain to repair than protein 
aggregates found in other diseases 
such as Huntington or prion disease. 
Second, the ﬁ  ndings suggest that the 
removal of plaques, once formed, may 
require more than simply halting the 
production of the Aβ peptide. However, 
as with all animal models, there are 
differences in comparison to the 
human disease, leading to both over- 
and underestimation of the relative 
importance of an effect in humans. The 
researchers do not yet know whether the 
plaques formed in mice may be more 
resistant to clearance than those seen in 
human disease. Conversely, the human 
brain, unlike the murine one, may have 
a more efﬁ  cient way of clearing amyloid 
plaques. What this study makes clear is 
that treatments directed at reducing Aβ
peptide production in AD will likely be 
most effective when started as early as 
possible.
Jankowsky JL, Slunt HH, Gonzales V, 
Savonenko AV, Wen JC, et al. (2005) 
Persistent amyloidosis following suppression 
of Aβ production in a transgenic model of 
Alzheimer disease. DOI: 10.1371/journal.
pmed.0020355
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C-type lectins are carbohydrate-binding cell surface molecules 
with a wide range of biological functions, many of which are 
related to immunity. Despite its name, dendritic cell–speciﬁ  c 
intercellular adhesion molecule-3 grabbing nonintegrin 
(DC-SIGN) is not only expressed on dendritic cells but also on 
specialized macrophages in the placenta and lung. A number 
of pathogens are known to interact with DC-SIGN, and some 
(including HIV) seem to have evolved to derive advantages from 
these interactions. 
Recent in vitro studies have shown that DC-SIGN can 
interact with Mycobacterium tuberculosis through a lipoglycan 
(a molecule composed of sugars and fatty acids) on the 
mycobacterial envelope called lipoarabinomannan (LAM). Trying 
to understand the role of DC-SIGN in tuberculosis (TB), Ludovic 
Tailleux and colleagues have focused on the interaction between 
M. tuberculosis and DC-SIGN–expressing cells in the lungs of 
human patients. 
The researchers studied a total of 74 individuals, including 40 
with TB, 11 with sarcoidosis, 14 with asthma, and nine control 
participants without active lung infection or inﬂ  ammation. All 
patients underwent bronchoalveolar lavage (BAL), a procedure 
that yields cells and proteins from the lower respiratory tract. 
The researchers then examined BAL cell populations after 
staining for various cell-surface markers by ﬂ  ow cytometry, 
and found that, in individuals without TB, very few alveolar 
macrophages (an average of 3%) expressed DC-SIGN. In 
contrast, an average of 30% (and up to 70%) of macrophages 
from patients with TB expressed the lectin. 
Tailleux and colleagues then incubated alveolar 
macrophages from a patient without TB ex vivo with M. 
tuberculosis, which resulted in infection of a subset of the cells. 
When the researchers examined DC-SIGN expression, they 
found that both infected and noninfected (bystander) cells 
in the population started to express DC-SIGN. The effect on 
bystander cells suggests that soluble factors from the microbe 
and/or the infected cells can induce DC-SIGN expression. 
Further functional ex vivo studies with cells from human 
patients indicated that DC-SIGN expression renders alveolar 
macrophages more susceptible to infection. 
The authors propose a scenario where complement receptors 
mediate most of the initial infection of alveolar macrophages in 
a naïve host, and where—once the infection is established—DC-
SIGN–expressing alveolar macrophages become preferential 
target cells for M. tuberculosis. Future work will be focused on 
identifying the soluble factors involved, and on determining 
whether DC-SIGN induction is an essential part of TB pathogenesis. 
Tailleux L, Pham-Thi N, Bergeron-Lafaurie A, Herrmann JL, 
Charles P, et al. (2005) DC-SIGN induction in alveolar macrophages 
deﬁ  nes privileged target host cells for mycobacteria in patients with 
tuberculosis. DOI: 10.1371/journal.pmed.0020381
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addition, they also studied the uncoupling 
protein 2 gene (UCP2)—a polymorphism 
in the promoter of this gene (UCP2 
−866G>A) (rs659366) has been 
associated in some, but not all, studies 
with increased risk of type 2 diabetes and 
impaired insulin secretion. 
The study took place from 1990 to 
2002, and enrolled patients from ﬁ  ve 
health centers in western Finland who 
were asked to have health checks 
every two to three years. Six percent 
(132) of people developed type 2 
diabetes. The key ﬁ  nding was that 
variants in the PPARG and CAPN10 genes 
increased future risk for type 2 diabetes, 
particularly in individuals with other risk 
factors. In individuals with a high risk 
of developing diabetes—with a fasting 
plasma glucose (FPG) of 5.6 millimoles 
per liter and body mass index (BMI) of 
30 kilograms per square meter—the 
hazard ratio increased to 21.2 for the 
combination of the PPARG PP and 
CAPN10 SNP43/44 GG/TT genotypes 
compared with those with low-risk 
genotypes with normal FPG and BMI less 
than 30 kilograms per square meter.
The researchers found that replacing 
the family history with the PPARG and 
CAPN10 variants in a predictive model 
(particularly in combination) gave 
almost the same strong prediction 
of subsequent type 2 diabetes. 
These genotypes also inﬂ  uenced the 
relationship between BMI and FPG, that 
is, in carriers of risk genotypes, there was 
a steeper increase in FPG for any given 
BMI.
The authors argue that the comparison 
of all the key gene variants side by side 
in one large study adds substantially 
to previous papers that have examined 
the effect of single gene variants on the 
risk of conversion to type 2 diabetes in 
interventional trials. 
However, it is important to understand 
the effect of these variants on the 
risk of disease in a large, prospective 
observational study before studying 
additive or synergistic effects with 
interactions such as lifestyle changes, 
they said. One of the problems of other 
studies has been that results have been 
different between different subgroups.
Although this study has limited power, 
as the largest of its kind it suggests that 
genetic variants in candidate genes can 
predict future type 2 diabetes, particularly 
in association with conventional risk 
factors such as obesity and abnormal 
glucose tolerance. With accumulating 
data from prospective studies, it should 
be possible to deﬁ  ne whether there will 
be a future role for genetic prediction of 
type 2 diabetes or whether these variants 
will inﬂ  uence response to prevention or 
treatment.
Lyssenko V, Almgren P, Anevski D, Orho-
Melander M, Sjögren M, et al. (2005) 
Genetic prediction of future type 2 diabetes. 
DOI: 10.1371/journal.pmed.0020345
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